Pink SheetPharmaMar and Boehringer Ingelheim are the latest companies to ask the European Medicines Agency to fast track its review of their planned EU marketing authorization applications (MAAs) for their resp
Pink SheetAlyftrek (vanzacaftor/tezacaftor/deutivacaftor), Vertex Pharmaceuticals’ next generation treatment for cystic fibrosis (CF) is one of six orphan products that the European Medicines Agency backed for
In VivoThe 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as th
Generics BulletinPreviously facing the prospect of a jury trial beginning next month, Jazz Pharmaceuticals has agreed in principle to pay $145m to resolve certain allegations that its US patent-litigation settlement a